Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Summary

This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug eptinezumab. The main goal of this study is to investigate long-term safety and tolerability of eptinezumab in Japanese migraine participants.

Timeline

Start

2021-09-21

Primary completion

2024-06-08

Completion

2024-06-08

Publications

• Takeshima T, Danno D, Imai N, Suzuki K, Ettrup A, Jensen S, Josiassen MK, Mittoux A, Matsumori Y. Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial. J Headache Pain. 2025 Nov 22;26(1):275. doi: 10.1186/s10194-025-02214-w.

Drugs

Indications